Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Conditions Studied
Interventions
- DRUG Teclistamab
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - UZ GENT — Ghent
- Universitaire Ziekenhuizen Leuven — Leuven
- Peking University First Hospital — Beijing
- West China Hospital Si Chuan University — Chengdu
- Sun Yat -Sen University Cancer Center — Guangzhou
- First affiliated Hospital of Zhejiang University — Hangzhou
California
- City of Hope — Duarte
- University of California San Francisco — San Francisco
- Stanford University Medical Center — Stanford
New York
- Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects — New York
- Memorial Sloan-Kettering Cancer Center — New York
Alberta
- Arthur J E Child Comprehensive Cancer Centre — Calgary
- Cross Cancer Institute — Edmonton
Alabama
- University of Alabama at Birmingham — Birmingham
Georgia
- Winship Cancer Institute Emory University — Atlanta
Michigan
- Barbara Ann Karmanos Cancer Institute — Detroit
North Carolina
- Levine Cancer Institute — Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2027-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04557098
The ClinicalTrials.gov registry entry for NCT04557098 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 1 intervention — of which Teclistamab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04557098 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04557098 about?
NCT04557098 is a clinical study titled "A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
What is the current status of trial NCT04557098?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2020-09-17. Estimated completion is 2027-05-28.
What conditions does trial NCT04557098 study?
This clinical trial studies the following conditions: Hematological Malignancies. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04557098?
The interventions under investigation include: Teclistamab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04557098?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04557098 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.